Physician profile
Jeevith Kanukunta
NPI 1851338727
$5,067.23
in general payments reported to CMS, 2019-2025
29 companies · $597 in 2025
The $597 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $577 · 2021: $547 · 2022: $1,104 · 2023: $823 · 2024: $783 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,183 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.55 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,385.52 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $753.38 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $619.73 | 2019-2025 | |
| Pfizer INC. | $435.44 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $227.54 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $206.00 | 2019-2024 | Xarelto |
| Penumbra, INC. | $193.97 | 2025 | Indigo System |
| Merck Sharp & Dohme LLC | $189.83 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $181.29 | 2019-2024 | Avvigo Guidance System |
| Astrazeneca Pharmaceuticals Lp | $87.02 | 2019-2023 | Farxiga |
| Abbott Laboratories | $81.23 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.92 | 2019-2023 | Jardiance |
| Chiesi USA, INC. | $73.49 | 2023-2025 | Kengreal, Juxtapid |
| Amarin Pharma, INC. | $63.77 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $62.13 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $58.65 | 2023-2024 | Injectafer |
| Esperion Therapeutics, INC. | $55.15 | 2021-2023 | Nexletol |
| Abiomed | $53.44 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.43 | 2025 | |
| Arbor Pharmaceuticals, INC. | $50.36 | 2020-2021 | |
| Medtronic, INC. | $35.88 | 2021-2023 | Onyx Frontier |
| Azurity Pharmaceuticals, INC. | $18.87 | 2023 | Edarbi |
| Cvrx, INC. | $18.56 | 2020 | |
| Edwards Lifesciences Corporation | $17.06 | 2021 | |
| Gilead Sciences, INC. | $17.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.88 | 2021 | |
| Cook Medical LLC | $15.39 | 2020 | |
| Medtronic Vascular, INC. | $13.10 | 2019 | |
| Cardiovascular Systems INC. | $7.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeevith Kanukunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.